Central Nervous System Introduction Flashcards

(26 cards)

1
Q

What structures comprise the CNS?

A

Brain
Upper spinal cord

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does neurotransmitters in teh CNS compare to the PNS?

A

Similar neurotransmitters are present, but CNS transmission is non-linear, involving complex networks and feedback loops

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What makes CNS control more nuanced than PNS signalling?

A

Interneurons complete feedback loops, influencing multiple neurons at different points, making theraputic prediction more challenging

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What roles do interneurons play in CNS transmission?

A

They create feedback loops, modifying signal transmission beyond simple linear pathways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Why is drug discovery for CNS disorders challenging?

A

1 - Complex neuronal interconnections -> Difficult to predict therapeutic outcomes
2 - Neurotransmitter adaptations -> Changes in synthesis and signalling can lead to tolerance, dependence, sisde effects
3 - Slow onset therapeutic effects -> Requires prolonged clinical management to determine the best treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the three categories of CNS signalling molecules?

A

1 - Fast neurotransmitters -> Glutamate, GABA, glycine (act on ligand-gated ion channels)
2 - Slow neurotransmitters -> Noradrenaline, dopamine (act on GPCRs)
3 - Neurotransmitters -> Neuropeptides, gaseous and lipid mediators, steroids (released by neurons, astrocytes, glial cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which neurotransmitters can act as both fast and slow transmitters?

A

Serotonin and Acetylcholine
They interact with both ligan-gated ion channels and GPCRs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What major coniditons affect the CNS?

A

Neurodegenerative disease
Anxiety and sleep disorders
Depression
Schizophrenia
Epilepst
Pain disorders

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How are anxiets disorders classified?

A
  1. Generalised anxiet disorder (GAD) -> Persistent anxiety without clear cause
  2. Panic disorder -> Sudden episodes of overwhelming fear
  3. Phobias -> Fear of specific objects or situations
  4. PTSD -> Trauma-induced anxiety symptoms
  5. OCD -> Ritualistic behaviours driven by anxiety
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the link between anxiety and sleep disorders?

A

Anxiety can exacerbate insomnia, but sleep disorders can exist independently, affecting health and quality of life

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is GABA?

A

A fast inhibitory neurotransmitter, exclusive to the CNS, present in 30% of synapses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the relationship between GABA and glutamate?

A

GABA and glutamate share a metabolic pathway
Glutamine -> Glutamate (via glutaminase)
Glutamate -> GABA (Via glutamic acid decarboxylase GAD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How is GABA signalling terminated?

A

Reuptake inot nerve terminals or surrounding glial cells, followed by recycling or metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the main types of GABA receptors?

A
  1. GABAA (Ligan-gated ion channel) -> Fast inhibition via chloride influx (hyperpolarisation)
  2. GABAB (GPCRs, mianly pre-synaptic) -> Inhibit voltage-gated calcium channels, reducing neurotransmitter release
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do bensodiazepines modulate GABAA receptors?

A

They bind allosterically at teh alpha-gamma subunit interface, increasing GABA affinity and chloride channel opening frequency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How do barbiturates differ from benzodiazepines?

A

Barbiturates directly open the chloride channel, leading to stronger inhibition and higher overdose risk

17
Q

What are clinical uses of GABAA receptor modulators?

A

Benzodiazepines (Diazepam, Temazepam) -> Anxiety, insomnia, anticonvulsant
Barbiturates (Zopiclone) -> Seizures, sedation
Flumazenil -> Benzodiazepine, overdonse antidote

18
Q

What is the monoamine theory of depression?

A

Depression rsults from a functional deficit of monoamine neurotransmitters (noradrenaline and serotonin), while mania results from a functional excess

19
Q

Whay is depression treatment challenging?

A

Varied symptoms (low mood, motivation loss, insomnia)
Complex neurochemical networks affect therapeutic success
Difficult to model depression in animals
Therapeutic lag (weeks to months for drug effects)

20
Q

How do antidepressents enchance monamine signalling?

A
  1. Inhibit reuptake -> Prolong monoamine presence in synaptic cleft
  2. Inhibit degradation -> Prevent monoamine breakdown, increasinf recycling and re-release
21
Q

What are the three major classes of antidepressants?

A
  1. Tricyclic Antidepressants (TCAs) -> Block noradrenaline and serotonin reuptale (high side effect profile)
  2. Selective Serotonin Reuptake Inhibitors (SSRIs) -> Fluoxetine (Prozac), more tolerable, first-line treatment
  3. Monoamine Oxidase Inhibitors (MAO-0s) -> Inhibit monoamine breakdown; risk of drug interactions
22
Q

Why are TCAs no longer first-line treatment?

A

High side effect profile (anticholinergic effects, cariotoxicity, risk in suicidal patients). Now mainly used for neuropathic pain treatment

23
Q

What is the advantage of SSRIs?

A

More specific for serotonin, better rolerated, lower toxicity than TCAs

24
Q

What other pathways cotnribute to depression?

A

Hypothalamic-pituitary-adrenal axis (HPA) -> Chronic stess activation
Excitotoxic glutamate action (NMDA receptors) -> Promotes neural apoptosis
Brain-derived neurotrophic factor (BDNF) -> Neuroprotective, enhances neurogenesis

25
What new treatment avenues are emerging?
Exploring NMDA receptor modulation, HPA axis regulation. BDNF-targeting drugs
26
Why does depression treatment require individualised care?
Neurochemical variations Environmental factors Multi-genic influences affect drug response